SitaAnt-M

Sitagliptin

• The First Oral DPP-4 inhibitor approved by the FDA for the treatment of TYPE2 DIABETES
• Effective in reducing HbA1c levels and fasting glucose levels & improving postprandial glucose excursions

Metformin

• Reduces hepatic gluconeogenesis and improves glucose uptake
• Experts protective effects on pancreatic islet cells